Enanta Pharmaceuticals
ENTA
180 hedge funds and large institutions have $917M invested in Enanta Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 64 increasing their positions, 53 reducing their positions, and 15 closing their positions.
160% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 15
21% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 53
15% more funds holding
Funds holding: 156 → 180 (+24)
0.86% more ownership
Funds ownership: 90.49% → 91.34% (+0.86%)
1% less capital invested
Capital invested by funds: $928M → $917M (-$11.2M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
85% less call options, than puts
Call options by funds: $269K | Put options by funds: $1.77M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$18.1M |
| 2 |
BlackRock
New York
|
+$10.3M |
| 3 |
State Street
Boston,
Massachusetts
|
+$7.82M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$4.84M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$3.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$12.6M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$6.65M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$6.23M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$6.22M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$6.21M |
ENTA Hedge Fund Activity: Q2 2020 in Review
180 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q2 2020, worth a combined $917M — down 1.2% from $928M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new ENTA positions and 15 closed out — a net gain of 24 holders — while 64 added to existing stakes and 53 trimmed.
The largest buyer was Ameriprise, adding an estimated $18.1M. The largest seller was Armistice Capital, cutting an estimated $12.6M.
- 180 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q2 2020, up from 156 in Q1 2020.
- Funds reported $917M of Enanta Pharmaceuticals stock for Q2 2020, down 1.2% quarter-over-quarter.
- 39 funds opened new Enanta Pharmaceuticals positions in Q2 2020 and 15 closed out, a net change of +24 holders.
- The largest Enanta Pharmaceuticals buyer in Q2 2020 was Ameriprise, an estimated $18.1M added.
- The largest Enanta Pharmaceuticals seller in Q2 2020 was Armistice Capital, an estimated $12.6M sold.
Based on aggregated 13F filings for Q2 2020.